Gilead and arcus announce amended collaboration and equity investment

Foster city, calif. & hayward, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) and arcus biosciences, inc. (nyse: rcus) today announced an amendment to their collaboration agreement and a separate equity investment by gilead of $320 million in arcus common stock at $21.00 per share. the equity investment and collaboration amendment enable accelerated growth of the companies' joint development programs that span multiple indications. additionally, johanna mercier, chief commercial.
RCUS Ratings Summary
RCUS Quant Ranking